{"id":"dual-release-hydrocortisone","safety":{"commonSideEffects":[{"rate":null,"effect":"Hyperglycemia"},{"rate":null,"effect":"Hypertension"},{"rate":null,"effect":"Osteoporosis"},{"rate":null,"effect":"Insomnia"},{"rate":null,"effect":"Mood changes"}]},"_chembl":{"chemblId":"CHEMBL2106309","moleculeType":"Small molecule","molecularWeight":"460.57"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"This formulation uses a modified-release technology to release hydrocortisone in two distinct phases—typically an immediate release component and a delayed release component—to replicate the diurnal pattern of endogenous cortisol secretion. By matching physiological cortisol levels throughout the day, dual-release hydrocortisone aims to improve efficacy while potentially reducing adverse effects associated with conventional immediate-release formulations.","oneSentence":"Dual-release hydrocortisone delivers the corticosteroid in two phases to mimic the body's natural cortisol rhythm, providing anti-inflammatory and immunosuppressive effects.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:10:11.288Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Adrenal insufficiency (primary or secondary)"},{"name":"Congenital adrenal hyperplasia"}]},"trialDetails":[{"nctId":"NCT07033039","phase":"NA","title":"Effects of Red and Infrared Photobiomodulation in Rhinoplasty at a Single Centre","status":"RECRUITING","sponsor":"University of Nove de Julho","startDate":"2026-01-30","conditions":"Rhinoplasty, Edema","enrollment":60},{"nctId":"NCT07451886","phase":"PHASE2","title":"Adjunctive Fludrocortisone in Septic Shock","status":"NOT_YET_RECRUITING","sponsor":"Chinese University of Hong Kong","startDate":"2026-04-01","conditions":"Sepsis, Septic Shock, Sepsis - to Reduce Mortality in the Intensive Care Unit","enrollment":32},{"nctId":"NCT06125951","phase":"PHASE2, PHASE3","title":"Effect of 10 mg Xanamem on Dementia Due to Alzheimer's Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"Actinogen Medical","startDate":"2024-04-12","conditions":"Dementia Moderate, Dementia, Mild, Alzheimer Disease","enrollment":247},{"nctId":"NCT03760835","phase":"PHASE4","title":"Congenital Adrenal Hyperplasia Once Daily Hydrocortisone Treatment","status":"RECRUITING","sponsor":"Federico II University","startDate":"2016-08-11","conditions":"Congenital Adrenal Hyperplasia","enrollment":150},{"nctId":"NCT06872944","phase":"EARLY_PHASE1","title":"Effect of Melatonin on Postoperative Pain After Simple Nephrectomy","status":"COMPLETED","sponsor":"Cairo University","startDate":"2025-03-21","conditions":"Pain Score (VAS) at 24 h Postoperatively","enrollment":40},{"nctId":"NCT07037043","phase":"PHASE3","title":"Hydrocortisone Plus Fludrocortisone in High-risk Patients Undergoing for Cardiac Surgery","status":"NOT_YET_RECRUITING","sponsor":"Centre Hospitalier Universitaire, Amiens","startDate":"2025-08","conditions":"Inflammation in Cardiac Surgery","enrollment":196},{"nctId":"NCT05063994","phase":"PHASE3","title":"Comparison of Chronocort Versus Standard Hydrocortisone Replacement Therapy in Participants Aged 16 Years and Over With Congenital Adrenal Hyperplasia","status":"COMPLETED","sponsor":"Neurocrine UK Limited","startDate":"2022-05-24","conditions":"Congenital Adrenal Hyperplasia","enrollment":55},{"nctId":"NCT05222152","phase":"PHASE2","title":"Chronocort Versus Plenadren Replacement Therapy in Adults With Adrenal Insufficiency","status":"COMPLETED","sponsor":"Neurocrine UK Limited","startDate":"2021-11-23","conditions":"Primary Adrenal Insufficiency","enrollment":58},{"nctId":"NCT05716607","phase":"NA","title":"Treatment Study in Patients Treated With Both Insulin & Hydrocortisone","status":"NOT_YET_RECRUITING","sponsor":"Vastra Gotaland Region","startDate":"2024-09","conditions":"Diabetes Mellitus, Adrenal Insufficiency, Polyglandular Autoimmune Syndrome","enrollment":16},{"nctId":"NCT06260462","phase":"PHASE3","title":"Effects of Steroid Replacement Therapy on Metabolic, Cardiovascular and Bone Outcomes in Adrenal Insufficiency","status":"COMPLETED","sponsor":"University of Palermo","startDate":"2012-01-01","conditions":"Adrenal Insufficiency","enrollment":88},{"nctId":"NCT04160676","phase":"NA","title":"Therapy With Hydrocortisone, Ascorbic Acid, Thamine in Patients With Sepsis","status":"COMPLETED","sponsor":"Tanta University","startDate":"2019-12-01","conditions":"Sepsis","enrollment":80},{"nctId":"NCT03509350","phase":"PHASE3","title":"Vitamin C, Thiamine, and Steroids in Sepsis","status":"COMPLETED","sponsor":"Emory University","startDate":"2018-08-22","conditions":"Sepsis","enrollment":501},{"nctId":"NCT03389555","phase":"PHASE2, PHASE3","title":"Ascorbic Acid, Corticosteroids, and Thiamine in Sepsis (ACTS) Trial","status":"COMPLETED","sponsor":"Beth Israel Deaconess Medical Center","startDate":"2018-02-09","conditions":"Sepsis, Septic Shock, Metabolic Disturbance","enrollment":205},{"nctId":"NCT02277587","phase":"PHASE4","title":"Dual RElease Hydrocortisone Versus conventionAl Glucocorticoid replaceMent Therapy in Hypocortisolism (DREAM)","status":"COMPLETED","sponsor":"University of Roma La Sapienza","startDate":"2014-03","conditions":"Primary Adrenal Insufficiency, Secondary Adrenal Insufficiency","enrollment":89},{"nctId":"NCT03335124","phase":"PHASE4","title":"The Effect of Vitamin C, Thiamine and Hydrocortisone on Clinical Course and Outcome in Patients With Severe Sepsis and Septic Shock","status":"TERMINATED","sponsor":"University Medical Centre Ljubljana","startDate":"2017-09-26","conditions":"Sepsis, Septic Shock, Critical Illness","enrollment":5},{"nctId":"NCT01374906","phase":"PHASE3","title":"Efficacy and Safety of Pasireotide Administered Monthly in Patients With Cushing's Disease","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2011-11-04","conditions":"Cushing's Disease","enrollment":150}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Plenadren"],"phase":"phase_3","status":"active","brandName":"dual-release hydrocortisone","genericName":"dual-release hydrocortisone","companyName":"University of Palermo","companyId":"university-of-palermo","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Dual-release hydrocortisone delivers the corticosteroid in two phases to mimic the body's natural cortisol rhythm, providing anti-inflammatory and immunosuppressive effects. Used for Adrenal insufficiency (primary or secondary), Congenital adrenal hyperplasia.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}